Bausch Health Companies Inc. faces a challenging day on the TSX, with shares down nearly 3%.
Bausch Health Companies Inc. (BHC.TO) saw its stock price drop today, closing at CA$6.68, down 2.91%. This decline follows the announcement that its product PrOKEDI has been added to the RAMQ formulary. However, investors appear concerned about the broader market conditions and the company's overall performance.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$2.53B
52W high
$11.97
52W low
$6.45
1W change
+0.73%
Beta
0.42
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to rise 1.9% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
+1.9% Upside
Current Price
C$6.88
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
50.1%
Annualized
90-Day Vol
42.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$5.75
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$6.48 | C$5.45 โ C$7.71 |
| 60 trading days | C$6.11 | C$4.78 โ C$7.80 |
| 90 trading days | C$5.75 | C$4.27 โ C$7.76 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: While Bausch Health's recent developments point to potential growth in the healthcare sector, todayโs stock performance shows that investors are cautious, reflecting the volatility and uncertainty surrounding the company.
Bausch Health Shares Drop 2.91% Today
The stock's decline highlights ongoing investor concerns, with a market cap of CA$2.53 billion and a profit margin of -11.47%.
Bull case
The inclusion of PrOKEDI in the RAMQ formulary could improve access to this injectable treatment for schizophrenia for patients in Quebec. This move might lead to increased sales and a stronger market presence for Bausch Health.
Bear case
Despite the positive news about PrOKEDI, the stock's drop indicates that investors are skeptical about the company's financial health and the challenges in the broader market. The negative profit margin and the upcoming earnings report add to this uncertainty.
Recent Developments
Bausch Health's announcement about PrOKEDI's listing in the RAMQ formulary is a significant milestone. This treatment could enhance patient access in Quebec. However, investors might be weighing these developments against the company's overall financial health.
Market Reaction
The 2.91% drop in BHC.TO shares reflects a cautious sentiment among investors. With a negative profit margin and an earnings report scheduled for July 29, uncertainty looms over the company's future performance. Investors should keep a close eye on these developments.
Looking Ahead
As Bausch Health prepares to announce its second-quarter results, the market will be watching closely to see how the company plans to tackle its challenges. The upcoming earnings call may offer more insights into its strategies and the potential impact of recent product launches.
Advertisement
